This study will evaluate the safety and efficacy of empasiprubart compared with placebo in adult participants with dermatomyositis (DM).
The study duration will be approximately 92 weeks for all participants. After the screening period, eligible participants will be randomized in a 2:1 ratio to receive either empasiprubart or placebo, respectively, during the treatment period (duration of 25 weeks). At the end of the treatment period, all the participants will enter a safety follow-up period (duration of 65 weeks).
Protocol Amendment History
15 amendments
This ClinicalTrials.gov record has been amended 15 times since 2024-02-22; most recent amendment 2025-09-22.
Status change: Recruiting → Active, Not Recruiting2025-09-22
Status change: Not Yet Recruiting → Recruiting2024-08-23